First-in-human study of palcitoclax (APG-1252), a novel dual Bcl-2/Bcl-xL inhibitor, demonstrated advantages in platelet safety while maintaining anticancer effect in U.S. patients with metastatic solid tumors.

Nehal J. Lakhani, Yifan Zhai, Qi Zeng et al.|Journal of Clinical Oncology|2020

Cited by 20